Comparing oncologic outcomes in patients undergoing surgery for oncocytic neoplasms, conventional oncocytoma, and chromophobe renal cell carcinoma.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
11 2019
Historique:
received: 30 03 2018
revised: 06 04 2019
accepted: 05 06 2019
pubmed: 28 8 2019
medline: 20 8 2020
entrez: 28 8 2019
Statut: ppublish

Résumé

Oncocytic neoplasms are renal tumors similar to oncocytoma, but their morphologic variations preclude definitive diagnosis. This somewhat confusing diagnosis can create treatment and surveillance challenges for the treating urologist. We hypothesize that these subtle morphologic variations do not drastically affect the malignant potential of these tumors, and we sought to demonstrate this by comparing clinical outcomes of oncocytic neoplasms to those of classic oncocytoma and chromophobe. We gathered demographic and outcomes data for patients with variant oncocytic tumors. Oncologic surveillance was conducted per institutional protocol in accordance with NCCN guidelines. Descriptive statistics were used to compare incidence of metastasis and death against those for patients with oncocytoma and chromophobe. Three hundred and fifty-one patients were analyzed: 164 patients with oncocytoma, 28 with oncocytic neoplasms, and 159 with chromophobe tumors. Median follow-up time for the entire cohort was 32.4 months, (interquartile range 9.2-70.0). Seventeen total patients (17/351, 4.9%) died during the course of the study. In patients with oncocytoma or oncocytic neoplasm, none were known to metastasize or die of their disease. Only chromophobe tumors >6 cm in size in our series demonstrated metastatic progression and approximately half of these metastasized tumors demonstrated sarcomatoid changes. Variant oncocytic neoplasms appear to have a natural course similar to classic oncocytoma. These tumors appear to have no metastatic potential, and oncologic surveillance may not be indicated after surgery.

Identifiants

pubmed: 31451335
pii: S1078-1439(19)30228-5
doi: 10.1016/j.urolonc.2019.06.002
pii:
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

811.e17-811.e21

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Chandra K Flack (CK)

Departments of Urology, Indiana University School of Medicine, Indianapolis, IN.

Adam C Calaway (AC)

Departments of Urology, Indiana University School of Medicine, Indianapolis, IN.

Brady L Miller (BL)

Department of Urology, University of Wisconsin School of Medicine, Madison, WI.

Maria M Picken (MM)

Departments of Pathology, Loyola University School of Medicine, Maywood, IL.

Dibson D Gondim (DD)

Departments of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN.

Muhammad T Idrees (MT)

Departments of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN.

E Jason Abel (EJ)

Department of Urology, University of Wisconsin School of Medicine, Madison, WI.

Gopal N Gupta (GN)

Departments of Urology, Loyola University School of Medicine, Maywood, IL.

Ronald S Boris (RS)

Departments of Urology, Indiana University School of Medicine, Indianapolis, IN. Electronic address: rboris@iupui.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH